Glenmark Pharmaceuticals

Glenmark Pharmaceuticals
Public company
Traded as BSE: 532296
NSE: GLENMARK)
Industry Pharmaceuticals, Drugs & Healthcare
Founded 1977
Founder Gracias Saldanha
Headquarters Mumbai, Maharashtra[1], India
Key people
Glenn Saldanha, MD & CEO[2]
Products Medicines and Vaccines
Revenue INR10.31 billion (US$160 million) (2009–2010)[3]
Number of employees
7,000[4]
Subsidiaries Glenmark Generics Ltd[5]
Website www.glenmarkpharma.com

Glenmark Pharmaceuticals is a pharmaceutical company headquartered in Mumbai, India.[6] It manufactures and markets generic formulation products and active pharmaceutical ingredients (API), both in the domestic and international markets. In the formulation business, its business spans segments such as Dermatology, Internal Medicine, Paediatrics, Gynaecology, ENT and Diabetes.

It has four manufacturing facilities for formulations and additional three facilities for APIs. These manufacturing facilities are located in the states of Maharashtra, Goa, Himachal Pradesh and Gujarat in India.

It operates in 95 countries through its subsidiaries, Glenmark Pharmaceuticals USA, Glenmark Pharmaceuticals UK. Glenmark Pharmaceuticals SA.[7]

References

  1. http://www.glenmarkpharma.com/UITemplate/HtmlContainer.aspx?res=P_GLN_CONTACT
  2. "If I were FM | Glenn Saldanha, managing director and CEO, Glenmark Pharmaceuticals – Economy and Politics". livemint.com. 1 July 2009. Retrieved 30 September 2010.
  3. "BSE Plus". Bseindia.com. Retrieved 30 September 2010.
  4. "Glenmark Pharmaceuticals Ltd. (2529483): Stock Quote & Company Profile – BusinessWeek". Investing.businessweek.com. Retrieved 30 September 2010.
  5. "Glenmark Pharmaceuticals | TopNews". Topnews.in. Retrieved 30 September 2010.
  6. "about Glenmark Pharmaceuticals" (PDF). ibef.org. Retrieved 30 September 2010.
  7. "Glenmark Pharmaceuticals acquires Bouwer Bartlett, South Africa". domain-b.com. 26 December 2005. Retrieved 30 September 2010.